Therefore, we suggest that Atg16L1 might serve as a therapeutic target for the treatment of altered phagocytosis-related diseases such as bacterial infection, inflammation, lupus nephritis, and cancer. This evidence concerns the gene ATG16L1 and lupus nephritis.